» Articles » PMID: 19604357

Predictors of Major Infections in Systemic Lupus Erythematosus

Overview
Publisher Biomed Central
Specialty Rheumatology
Date 2009 Jul 17
PMID 19604357
Citations 102
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Infections commonly complicate the course of systemic lupus erythematosus (SLE). Our aim is to investigate the clinical predictors of major infections in patients with SLE.

Methods: A nested case-control study design was used within the prospective Lupus-Cruces cohort. The endpoints of the study were major infections. Cases were defined as patients with a major infection. Two controls (SLE patients without major infections), matched for time of follow-up until the event and age at diagnosis, were selected for each case. Univariate analysis and logistic regression models were used for the analysis of data.

Results: Two hundred and forty-nine patients (83 cases, 166 controls) were selected. Eighty-three episodes of major infections were analyzed; E. coli, S. aureus, M. tuberculosis and S. pneumoniae being the most frequent isolates. Univariate analysis identified several variables related with infection: lung and renal involvement, at or previous to the study point; leukopenia at the study point; antiphospholipid antibody-positivity and treatment with prednisone within 3 months previous to the study point, and the dose of prednisone received. Treatment with antimalarials, on the other hand, showed a strong inverse association with major infections. Logistic regression models identified treatment with antimalarials (odds ratio (OR) = 0.06, 95% confidence interval (CI) = 0.02 to 0.18), prednisone dose (OR = 1.12, 95% CI = 1.04 to 1.19) and lung involvement (OR = 4.41, 95% CI = 1.06 to 18.36) as significant and independent predictors of major infections. No significant interactions among these three variables were found. Further adjustment for potential confounders related with antimalarial treatment did not change the results.

Conclusions: The risk of major infections in patients with SLE is mostly influenced by treatment. Prednisone treatment, even at moderate doses, increases the risk, whilst antimalarials have a protective effect.

Citing Articles

Why is it so difficult to understand why we don't understand human systemic lupus erythematosus? Contemplating facts, conflicts, and impact of "the causality cascade paradigm".

Rekvig O Front Immunol. 2025; 15:1507792.

PMID: 39936150 PMC: 11811100. DOI: 10.3389/fimmu.2024.1507792.


Infection-Associated Flares in Systemic Lupus Erythematosus.

Ramirez G, Calabrese C, Secci M, Moroni L, Gallina G, Benanti G Pathogens. 2024; 13(11).

PMID: 39599487 PMC: 11597141. DOI: 10.3390/pathogens13110934.


Use of Glucocorticoids in SLE: A Clinical Approach.

Martin-Iglesias D, Paredes-Ruiz D, Ruiz-Irastorza G Mediterr J Rheumatol. 2024; 35(Suppl 2):342-353.

PMID: 39193186 PMC: 11345604. DOI: 10.31138/mjr.230124.uos.


Paracoccidioidomycosis: An uncommon cause of discitis in lupus.

Appenzeller S, Costallat L, Ramos M, de Oliveira Andrade S, Reis F Rev Soc Bras Med Trop. 2024; 57:e00922.

PMID: 39082529 PMC: 11290868. DOI: 10.1590/0037-8682-0191-2024.


SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort.

Rua-Figueroa I, Garcia de Yebenes M, Martinez-Barrio J, Izquierdo M, Calvo Alen J, Fernandez-Nebro A Lupus Sci Med. 2024; 11(1).

PMID: 38589223 PMC: 11015315. DOI: 10.1136/lupus-2023-001096.


References
1.
Duffy K, Duffy C, Gladman D . Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol. 1991; 18(8):1180-4. View

2.
Pryor B, Bologna S, Kahl L . Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 1996; 39(9):1475-82. DOI: 10.1002/art.1780390906. View

3.
Cervera R, Khamashta M, Font J, Sebastiani G, Gil A, Lavilla P . Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82(5):299-308. DOI: 10.1097/01.md.0000091181.93122.55. View

4.
Houssiau F, Vasconcelos C, DCruz D, Sebastiani G, Garrido Ed E, Danieli M . Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002; 46(8):2121-31. DOI: 10.1002/art.10461. View

5.
Alarcon G, McGwin G, Bertoli A, Fessler B, Calvo-Alen J, Bastian H . Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007; 66(9):1168-72. PMC: 1955128. DOI: 10.1136/ard.2006.068676. View